[en] BACKGROUND: Accelerated step-up or anti-tumor necrosis factor (TNF) before first remission is currently not recommended in pediatric Crohn's disease. METHODS: Five-year follow-up data from a prospective observational cohort of children diagnosed with Crohn's disease in Belgium were analyzed. Disease severity was scored as inactive, mild, or moderate to severe. Remission or inactive disease was defined as sustained if lasting >/=2 years. Univariate analyses were performed between anti-TNF-exposed versus naive patients and anti-TNF before versus after first remission and correlations assessed with primary outcomes average disease severity and sustained remission. RESULTS: A total of 91 patients (median [IQR] age 12.7 [10.9-14.8] yrs, 53% male) were included. Disease location was 12% L1, 23% L2, and 64% L3 with 76% upper gastrointestinal and 30% perianal involvement. Disease severity was 25% mild and 75% moderate to severe. Of 66 (73%) anti-TNF-exposed patients, 34 (52%) had accelerated step-up. Anti-TNF use was associated with age (13.1 [11.5-15.2] versus 11.8 [8.7-13.8] yrs; P < 0.05), L2 (29% versus 8%; P = 0.04), and average disease severity (1.7 [1.4-1.9] versus 1.4 [1.3-1.6]; P < 0.001). Duration of anti-TNF correlated with average disease severity (r = 0.32, P = 0.002). Accelerated step-up was also associated with age (13.3 [12.1-15.9] versus 12.5 [10.2-14.1]; P = 0.02) and average disease severity (1.8 [1.6-1.9] versus 1.6 [1.3-1.8]; P = 0.002). Duration of sustained remission was similar in all patients, and no serious infections, cancer, or deaths were reported. CONCLUSIONS: Anti-TNF therapy and accelerated step-up in older patients with more severe disease leads to beneficial long-term outcomes.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Wauters, Lucas
Smets, Francoise
De Greef, Elisabeth
Bontems, Patrick
Hoffman, Ilse
Hauser, Bruno
Alliet, Philippe
Arts, Wim
Peeters, Harald
Van Biervliet, Stephanie
Paquot, Isabelle
Van de Vijver, Els
De Vos, Martine
Bossuyt, Peter
Rahier, Jean-Francois
Dewit, Olivier
Moreels, Tom
Franchimont, Denis
Muls, Vincianne
Fontaine, Fernand
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423-439.
Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
Wilson DC, Thomas AG, Croft NM, et al. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2010;50(suppl 1):S14-S34.
Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873.
Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012;143:365-374.e2.
D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-A vs an immunomodulator in children with Crohn's disease. Gastroenterology. 2014;146:383-391.
Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152:1901-1914.e3.
De Bie CI, Paerregaard A, Kolacek S, et al. Disease phenotype at diagnosis in pediatric Crohn's disease: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis. 2013;19:378-385.
De Greef E, Mahachie John JM, Hoffman I, et al. Profile of pediatric Crohn's disease in Belgium. J Crohns Colitis. 2013;7:e588-e598.
De Greef E, Hoffman I, Smets F, et al. Paediatric Crohn disease: disease activity and growth in the BELCRO cohort after 3 Years follow-up. J Pediatr Gastroenterol Nutr. 2016;63:253-258.
Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795-806.
Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321.
Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114-1122.
Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135:1106-1113.
Savoye G, Salleron J, Gower-Rousseau C, et al. Clinical predictors at diagnosis of disabling pediatric Crohn's disease. Inflamm Bowel Dis. 2012;18:2072-2078.
Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr. 2009;49:183-190.
Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8:1179-1207.
Markowitz J. Can we change the natural history of Crohn's disease with early immunomodulation? Dig Dis. 2014;32:345-350.
Punati J, Markowitz J, Lerer T, et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis. 2008; 14:949-954.
Lee YM, Kang B, Lee Y, et al. Infliximab top-down strategy is superior to step-up in maintaining long-term remission in the treatment of pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2015;60:737-743.
Kang B, Choi SY, Kim HS, et al. Mucosal healing in paediatric patients with moderate-to-severe luminal Crohn's disease under combined immunosuppression: escalation versus early treatment. J Crohns Colitis. 2016; 10:1279-1286.
Hyams JS. Risk/benefit strategies must be employed in the management of pediatric Crohn's disease. Dig Dis. 2009;27:291-296.
Walters TD, Hyams JS. Can early anti-TNF-A treatment be an effective therapeutic strategy in children with Crohn's disease? Immunotherapy. 2014;6:799-802.
Dubinsky M. Have we changed the natural history of pediatric Crohn's disease with biologics? Dig Dis. 2014;32:360-363.
Siegel CA, Siegel LS, Hyams JS, et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis. 2011;17:30-38.
Malmborg P, Grahnquist L, Ideström M, et al. Presentation and progression of childhood-onset inflammatory bowel disease in Northern Stockholm County. Inflamm Bowel Dis. 2015;21:1098-1108.
Malmborg P, Hildebrand H. The emerging global epidemic of paediatric inflammatory bowel disease-causes and consequences. J Intern Med. 2016;279:241-258.
Otley A, Loonen H, Parekh N, et al. Assessing activity of pediatric Crohn's disease: which index to use? Gastroenterology. 1999;116:527-531.
